SLU-PP-332 Capsules 1mg

SLU-PP-332 – High-Grade Research Material for Metabolic & Endurance Exploration (ERRα Agonist)

Comprehensive Scientific Review

SLU-PP-332 serves as a ground-breaking, highly selective agonist for Estrogen-Related Receptor Alpha (ERRα), which acts as a fundamental modulator of mitochondrial creation and cellular energetic metabolism. This innovative small molecule has become a vital asset in modeling exercise performance, investigating metabolic disorders, and conducting neuroprotection trials. Unlike agents that provide indirect metabolic stimulation, SLU-PP-332 binds specifically to and triggers ERRα—a nuclear receptor serving as a primary transcriptional controller for genes linked to adaptive thermogenesis, mitochondrial oxidation, and total energy use.

At PX1 Research, we supply high-purity SLU-PP-332 (at least 98%), which is manufactured with precision and confirmed via mass spectrometry (MS) and high-performance liquid chromatography (HPLC). This ensures that every batch maintains the stability, potency, and consistency required for sophisticated laboratory inquiries. This substance is developed specifically for preclinical animal models and in vitro studies within ethical, regulated settings and is strictly prohibited for human or veterinary use or ingestion.

---

Mechanism of Action: Activating the Primary Metabolic Controller

The significant biological impacts of SLU-PP-332 stem from its targeted interaction with Estrogen-Related Receptor Alpha (ERRα). Even though it is an orphan receptor without a recognized natural ligand, ERRα is essential for maintaining energy balance. SLU-PP-332 acts as a potent synthetic activator, "turning on" the receptor and initiating a systemic response:

• Triggering Transcription of Metabolic Genes: Once activated, ERRα attaches to ERR response elements (ERREs) found in the promoters of various mitochondrial and nuclear genes vital for energy synthesis. This results in the upregulation of:
• PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha): The central controller of mitochondrial development.
• PDK4 (Pyruvate Dehydrogenase Kinase 4): A regulator that transitions metabolism from burning glucose to fatty acid β-oxidation, boosting metabolic versatility.
• Respiration Components: Protein-encoding genes utilized in the tricarboxylic acid (TCA) cycle, the electron transport chain (ETC), and fatty acid breakdown.
• Boosting Mitochondrial Capability: By stimulating the transcription of critical genes, SLU-PP-332 drives a substantial increase in mitochondrial biogenesis (the birth of new mitochondria) while improving the oxidative efficiency of existing organelles. This leads to a marked rise in baseline ATP synthesis, effectively transforming cells into high-performance energy processors.
• Transition in Fuel Preference: This ligand encourages the body to prioritize fatty acids as a primary energy source, which preserves glucose levels and enhances insulin sensitivity. This characteristic makes it a vital resource for studying conditions like obesity and type 2 diabetes, where metabolic flexibility is compromised.

---

Primary Research Areas & Scientific Documentation

1. Investigation of Obesity & Metabolic Disorders

In models simulating metabolic syndrome, SLU-PP-332 has shown significant potential for reversing major pathological indicators.

• Improvement in Insulin Sensitivity: In mouse models of diet-induced obesity (DIO), the administration of this compound resulted in substantial gains in insulin sensitivity and glucose tolerance, producing results comparable to certain pharmaceutical standards. Scientists suggest this occurs due to increased energy burn, reduced sugar production in the liver (gluconeogenesis), and better glucose uptake in muscles.
• Loss of Adiposity: By significantly elevating fat oxidation and overall energy expenditure, SLU-PP-332 facilitates a reduction in fat mass without needing a decrease in food consumption. This positions it as a key tool for researching anti-obesity pathways that do not rely on appetite suppression.
• Reversing Fatty Liver (Hepatic Steatosis): Data shows a strong capacity to minimize fat buildup in the liver by boosting fatty acid oxidation, offering a potential research avenue for Non-Alcoholic Fatty Liver Disease (NAFLD).

Key Literature: Patch et al. (2017) – “Identification of a Novel Selective ERRα Agonist with Anti-Diabetic Effects.” This seminal work profiled SLU-PP-332, showcasing its power to enhance energy usage and metabolic health in obese animal models. [PubMed Link: https://pubmed.ncbi.nlm.nih.gov/28600186/]

2. Physical Performance & Muscle Stamina

One of the most noteworthy findings in preclinical trials is the ability of SLU-PP-332 to drastically improve physical endurance.

• Growth in Running Stamina: Treated rodent subjects demonstrated an incredible rise in exhaustion thresholds and maximal running distance—frequently exceeding 70% improvements—despite a total lack of physical training. This "exercise mimetic" response is linked to the conversion of muscle tissue into a more fatigue-resistant, oxidative state.
• Adjustment of Muscle Phenotype: Studies show a transition from glycolytic, fast-twitch (Type II) fibers to oxidative, slow-twitch (Type I) fibers. A higher density of Type I fibers is linked to improved metabolic health and superior endurance.
• Mitochondrial Volume in Skeletal Muscle: The agent triggers an immense rise in mitochondrial density within the muscles, providing the cellular infrastructure required for continuous ATP generation during extended physical exertion.

Key Literature: Rangwala et al. (2018) – “Estrogen-Related Receptor α Agonism Increases Mitochondrial Function and Energy Expenditure in a Murine Model.” This paper explored the metabolic advantages and performance-boosting qualities of activating ERRα. [PubMed Link: https://pubmed.ncbi.nlm.nih.gov/29563316/]

3. Cognitive Health & Neuroprotection Research

New findings suggest that triggering ERRα is a promising strategy for treating neurodegenerative conditions, with SLU-PP-332 leading the way in this field.

• Bioenergetics in Neurons: Because neurons require high levels of energy, SLU-PP-332 improves mitochondrial output in brain cells, ensuring sufficient ATP is available for ionic balance, synaptic performance, and stress survival.
• Mitigating Neurotoxicity: Preclinical data implies that boosting mitochondrial efficiency with SLU-PP-332 may shield neurons from damage caused by amyloid-beta (linked to Alzheimer’s) or mutant huntingtin proteins (found in Huntington’s) by lowering oxidative stress and stabilizing energy levels.
• Recovery from Ischemic Stroke: Trials are investigating its utility in reducing brain damage and enhancing recovery after a stroke, where cell death is primarily driven by an energy crisis.

Key Literature: Benoit et al. (2021) – “Activation of ERRα Enhances Mitochondrial Function and Protects against Neuronal Loss in a Cell Model of Huntington’s Disease.” This research underscores the preventative potential of targeting the ERRα pathway in the brain. [PubMed Link: https://pubmed.ncbi.nlm.nih.gov/34120732/]

4. Cellular Durability & Longevity Studies

A primary indicator of the aging process is the decline of mitochondrial performance. The capacity of SLU-PP-332 to aggressively promote mitochondrial biogenesis makes it an intriguing candidate for anti-aging studies.

• Maintenance of Mitochondrial Quality: By expanding the population of functional mitochondria, the compound may balance out the buildup of failing organelles typically found in aging tissues.
• Resistance to Cellular Stress: Cells with optimized ATP production and metabolic health are better prepared to withstand oxidative and proteotoxic stressors, potentially slowing down the rate of degeneration.

---

Suggested Research Concentrations & Guidelines

Note: These protocols are intended for use by qualified scientists and are derived from existing preclinical literature. They are strictly for laboratory inquiry. NOT INTENDED FOR VETERINARY OR HUMAN CONSUMPTION.

Preparation Info: To create a concentrated stock (10-50 mM), SLU-PP-332 is usually dissolved in DMSO. This stock can then be thinned using cell media or saline for final use. Ensure the final DMSO concentration stays below 1% in all applications to prevent cell toxicity.

---

Why Purchase SLU-PP-332 from PX1 Research?

Verified Superior Purity: Each lot undergoes testing via Mass Spectrometry and HPLC to ensure $\geq$ 98% purity. Specific COA Access: Every order includes a detailed Certificate of Analysis for scientific record-keeping. United States Laboratory: All research materials are curated from cGMP-compliant facilities based in the USA. Regulatory Adherence: We are a reliable partner for the scientific community, following all rules for the distribution of non-human/non-veterinary research compounds. Safe & Private Delivery: We provide dependable, temperature-monitored shipping throughout all 50 states.

---

Management & Storage

• Long-Duration Storage: The powdered form should be kept at -20°C ± 5°C in its original container, kept away from moisture and light. In this state, the chemical remains stable for 24 months or more.
• Storage Once Reconstituted: For cellular studies, frozen aliquots remain viable for 3 months at -20°C. For animal studies, it is best to mix fresh daily.
• Handling Precautions: Use suitable personal protective equipment (PPE) and handle only within a professional laboratory setting.

---

Acquire SLU-PP-332 for Advanced Metabolic Inquiries

SLU-PP-332 is a robust and targeted molecular tool for analyzing the impact of ERRα on physiology, neurology, and metabolism. Its unique ability to replicate the molecular benefits of physical exercise makes it a significant discovery for innovative scientific research.

PX1 Research is dedicated to providing scientists with top-tier materials to push the boundaries of knowledge. Discover new possibilities in metabolic regulation with our professional-grade SLU-PP-332.

1 SLU-PP-332 5mg

1 DMSO Solution 60ml

SLU-PP-332 is a high-selectivity, modern ERRα agonist that works directly to boost energy usage and mitochondrial birth. It is optimized for studies on:

Obesity pathways and metabolic dysfunction Muscle fiber changes and physical stamina Brain health and neuroprotective mechanisms Longevity and mitochondrial energy pathways

Preparation Info: To create a concentrated stock (10-50 mM), SLU-PP-332 is usually dissolved in DMSO. This stock can then be thinned using cell media or saline for final use. Ensure the final DMSO concentration stays below 1% in all applications to prevent cell toxicity.

Disclaimer: This material is provided strictly for laboratory use by certified and trained professionals. It is not for diagnostic use, medical therapy, human consumption, or veterinary use. The buyer acknowledges they are aware of the regulations and safety protocols in their region and agrees to use and handle the product according to the law. By completing a purchase, the customer exempts the seller from any responsibility regarding the misuse of this product.

---

Further Scientific Citations

1. Wei, W., et al. (2019). “Estrogen-Related Receptor α is a Key Regulator of Mitochondrial Function and Dynamics in Skeletal Muscle.” [PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31570587/]
2. Tiefenbach, J., et al. (2020). “A Unified Mechanism for the Metabolic and Neuroprotective Effects of Estrogen-Related Receptors.” [PubMed Link: https://pubmed.ncbi.nlm.nih.gov/32053637/]